Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2011

01-04-2011 | Article

Serum C-reactive protein level and prediabetes in two Asian populations

Authors: C. Sabanayagam, A. Shankar, S. C. Lim, J. Lee, E. S. Tai, T. Y. Wong

Published in: Diabetologia | Issue 4/2011

Login to get access

Abstract

Aims/Hypothesis

Prediabetes, an early stage in the hyperglycaemic continuum, increases the future risk of developing diabetes and cardiovascular disease (CVD). C-reactive protein (CRP), a marker of inflammation, is associated with diabetes and CVD. However, studies examining the association between CRP and prediabetes among participants without diabetes are limited.

Methods

We analysed data from two large population-based studies in Singapore: the Singapore Prospective Study Programme (SP2, n = 4,252 Chinese, Malay and Indians aged ≥24 years) and the Singapore Malay Eye Study (SiMES, n = 2,337 Malays aged 40–80 years), participants of which were free of diabetes mellitus. Prediabetes was defined as glycated haemoglobin of 5.7–6.4% in SiMES (n = 1,231); fasting plasma glucose of 5.6–6.9 mmol/l in SP2 (n = 386).

Results

Elevated high sensitivity CRP (hsCRP) levels were found to be associated with prediabetes after adjusting for age, sex, race–ethnicity, education, smoking, alcohol consumption, hypertension, BMI and total cholesterol. Comparing those with hsCRP <1 mg/l (referent), the OR (95% confidence interval) of prediabetes in persons with hsCRP 1–3 mg/l and >3 mg/l was 1.31 (0.99–1.74) and 2.17 (1.61–2.92), p trend < 0.0001 in SP2; 1.23 (1.00–1.52) and 1.31 (1.06–1.64), p trend = 0.02 in SiMES. In subgroup analysis, the association was stronger in women, Chinese and Malays, and participants with BMI <25 kg/m2.

Conclusions

Data from two population-based Asian cohorts suggest that elevated serum hsCRP levels are associated with prediabetes.
Literature
1.
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diab Care 21:1414–1431
2.
Fox CS, Coady S, Sorlie PD et al (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115:1544–1550PubMed
3.
Milicevic Z, Raz I, Beattie SD et al (2008) Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diab Care 31(Suppl 2):S155–S160
4.
Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109: II2–10
5.
Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMed
6.
Chase HP, Cooper S, Osberg I et al (2004) Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 53:2569–2573PubMed
7.
Doi Y, Kiyohara Y, Kubo M et al (2005) Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28:2497–2500PubMed
8.
Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V (2009) Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. J Clin Endocrinol Metab 94:2099–2105PubMed
9.
Buckley DI, Fu R, Freeman M, Rogers K, Helfand M (2009) C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med 151:483–495PubMed
10.
Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ (2008) C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 1:92–97PubMed
11.
Aronson D, Bartha P, Zinder O et al (2004) Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 21:39–44PubMed
12.
de RN P, Peila R, Ding J et al (2006) Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 29:1902–1908
13.
Nakanishi N, Shiraishi T, Wada M (2005) Association between fasting glucose and C-reactive protein in a Japanese population: the Minoh study. Diabetes Res Clin Pract 69:88–98PubMed
14.
Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M (2002) Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 155:65–71PubMed
15.
Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med 19:939–943PubMed
16.
Anonymous (2010) Standards of medical care in diabetes–2010. Diabetes Care 33(Suppl 1):S11–S61
17.
Ford ES, Zhao G, Li C (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55:1310–1317PubMed
18.
Haffner SM (2003) Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61(Suppl 1):S9–S18PubMed
19.
Doi Y, Kiyohara Y, Kubo M et al (2005) Relationship between C-reactive protein and glucose levels in community-dwelling subjects without diabetes: the Hisayama Study. Diabetes Care 28:1211–1213PubMed
20.
Lin J, Zhang M, Song F et al (2009) Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population. Diabetes Metab Res Rev 25:219–223PubMed
21.
Yamada S, Gotoh T, Nakashima Y et al (2001) Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School cohort study. Am J Epidemiol 153:1183–1190PubMed
22.
Kao PC, Shiesh SC, Wu TJ (2006) Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci 36:163–169PubMed
23.
Sabanayagam C, Tai ES, Shankar A, Lee J, Sun C, Wong TY (2009) Retinal arteriolar narrowing increases the likelihood of chronic kidney disease in hypertension. J Hypertens 27:2209–2217PubMed
24.
Foong AW, Saw SM, Loo JL et al (2007) Rationale and methodology for a population-based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiol 14:25–35PubMed
25.
Barros AJ, Hirakata VN (2003) Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3:21PubMed
26.
Barzilay JI, Abraham L, Heckbert SR et al (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384–2389PubMed
27.
Choi KM, Lee J, Lee KW et al (2004) Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 64:99–106PubMed
28.
Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM (2003) Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822–1830PubMed
29.
Yatagai T, Nakamura T, Nagasaka S et al (2004) Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res Clin Pract 63:19–26PubMed
30.
Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171–3182PubMed
31.
Caballero AE (2004) Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr Diab Rep 4:237–246PubMed
32.
Thorand B, Baumert J, Kolb H et al (2007) Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diab Care 30:854–860
33.
Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB (1996) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 143:228–239PubMed
34.
Durenberg-Yap M, Chew SK, Deurenberg P (2002) Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes Rev 3:209–215
35.
Cowie CC, Rust KF, Ford ES et al (2009) Full accounting of diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. Diab Care 32:287–294
36.
Evans DJ, Barth JH, Burke CW (1988) Body fat topography in women with androgen excess. Int J Obes 12:157–162PubMed
37.
Samy N, Hashim M, Sayed M, Said M (2009) Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers 26:163–170PubMed
38.
Chambers JC, Eda S, Bassett P et al (2001) C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European Whites. Circulation 104:145–150PubMed
39.
Mahajan A, Tabassum R, Chavali S et al (2009) High-sensitivity C-reactive protein levels and type 2 diabetes in urban North Indians. J Clin Endocrinol Metab 94:2123–2127PubMed
40.
Mohan V, Deepa R, Velmurugan K, Premalatha G (2005) Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-6). Diabet Med 22:863–870PubMed
41.
Pradhan AD, Cook NR, Buring JE, Manson JE, Ridker PM (2003) C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 23:650–655PubMed
42.
Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843PubMed
43.
Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMed
44.
Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415PubMed
45.
Lear SA, Kohli S, Bondy GP, Tchernof A, Sniderman AD (2009) Ethnic variation in fat and lean body mass and the association with insulin resistance. J Clin Endocrinol Metab 94:4696–4702PubMed
46.
Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE (1999) Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84:137–144PubMed
Metadata
Title
Serum C-reactive protein level and prediabetes in two Asian populations
Authors
C. Sabanayagam
A. Shankar
S. C. Lim
J. Lee
E. S. Tai
T. Y. Wong
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2052-5

Other articles of this Issue 4/2011

Diabetologia 4/2011 Go to the issue

Article

Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis

Short Communication

Effects of a lifestyle intervention in metabolically benign and malign obesity

Erratum

Erratum to: Association of glucose metabolism with diastolic function along the diabetic continuum

Article

Genetic predisposition to obesity leads to increased risk of type 2 diabetes

Article

Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and albuminuria in individuals with normal kidney function: evidence from a family-based study

Article

The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits